NOMD Stock Analysis: Nomad Foods | NYSE
Packaged Foods | NYSE, USA | Market Cap: 1.665m USD | 12M Return: -18.2% | VGG6564A1057 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.6M
EPS Trend: 44.5%
Qual. Beats: 2
Rev. Trend: -44.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nomad Foods Limited is a UK-based frozen food manufacturer, marketer, and distributor operating across the United Kingdom and international markets. The companys product portfolio spans frozen fish (fish fingers, coated fish, natural fish), ready-to-cook vegetables, frozen poultry and meat products (nuggets, grills, burgers), ready-made meals (noodles, pasta, lasagna, pancakes), ice creams, and ancillary items such as soups, pizzas, bakery goods, and meat substitutes.
Products are distributed primarily to supermarkets and food retail chains under a portfolio of established brands, including Birds Eye, Green Cuisine, iglo, Findus, Aunt Bessies, Goodfellas, Frikom, Ledo, La Cocinera, and Belviva. Nomad Foods was founded in 2014 and is headquartered in Woking, United Kingdom.
As a packaged foods company in the consumer staples sector, Nomad Foods benefits from the typically recession-resistant demand profile of frozen convenience foods, which rely on extended shelf life and established cold-chain distribution. The companys brand-led, multi-category strategy-spanning fish, meat alternatives, and meals-reflects a common approach in the European packaged frozen food industry of leveraging heritage brands acquired through roll-up consolidation to achieve cross-market scale.
- European frozen food volumes drive organic revenue growth
- Fish and commodity input costs pressure gross margins
- Bolt-on acquisitions and deleveraging shape capital allocation
| Net Income: 125.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -2.54 > 1.0 |
| NWC/Revenue: 3.54% < 20% (prev 0.89%; Δ 2.65% < -1%) |
| CFO/TA 0.04 > 3% & CFO 284.1m > Net Income 125.6m |
| Net Debt (2.13b) to EBITDA (342.3m): 6.21 < 3 |
| Current Ratio: 1.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.1m) vs 12m ago -8.19% < -2% |
| Gross Margin: 26.92% > 18% (prev 29.06%; Δ -2.14% > 0.5%) |
| Asset Turnover: 46.86% > 50% (prev 48.15%; Δ -1.28% > 0%) |
| Interest Coverage Ratio: 2.11 > 6 (EBIT TTM 232.2m / Interest Expense TTM 110.2m) |
| A: 0.02 (Total Current Assets 1.19b - Total Current Liabilities 1.08b) / Total Assets 6.38b |
| B: 0.20 (Retained Earnings 1.29b / Total Assets 6.38b) |
| C: 0.04 (EBIT TTM 232.2m / Avg Total Assets 6.38b) |
| D: 0.65 (Book Value of Equity 2.52b / Total Liabilities 3.86b) |
| Altman-Z'' = 1.70 = BB |
| DSRI: 0.98 (Receivables 438.8m/458.4m, Revenue 2.99b/3.07b) |
| GMI: 1.08 (GM 29.06% / 26.92%) |
| AQI: 1.00 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 0.97 (Revenue 2.99b / 3.07b) |
| TATA: -0.02 (NI 125.6m - CFO 284.1m) / TA 6.38b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of August 28, 2026, the stock is trading at USD 11.99 with a total of 1,556,380 shares traded. Over the past week, the price has changed by +3.27%, over one month by +2.08%, over three months by +20.47% and over the past year by -18.17%.
Current recommended Stop Loss: 11.20 (which is 6.6% or 1.8 ATR below the current price).
Nomad Foods has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy NOMD.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.8 | 14.8% |
Market Cap EUR = 1.43b (1.66b USD * 0.8578 USD.EUR)
P/E Trailing = 11.495
P/E Forward = 11.1359
P/S = 0.5004
P/B = 0.5724
P/EG = 1.38
Revenue TTM = 2.99b EUR
EBIT TTM = 232.2m EUR
EBITDA TTM = 342.3m EUR
Long Term Debt = 2.20b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 33.7m EUR (from shortTermDebt, last quarter)
Debt = 2.40b EUR (from shortLongTermDebtTotal, last quarter) + Leases 89.3m
Net Debt = 2.13b EUR (calculated: Debt 2.40b - CCE 273.3m)
Enterprise Value = 3.56b EUR (1.43b + Debt 2.40b - CCE 273.3m)
Interest Coverage Ratio = 2.11 (Ebit TTM 232.2m / Interest Expense TTM 110.2m)
EV/FCF = 17.36x (Enterprise Value 3.56b / FCF TTM 204.8m)
FCF Yield = 5.76% (FCF TTM 204.8m / Enterprise Value 3.56b)
FCF Margin = 6.85% (FCF TTM 204.8m / Revenue TTM 2.99b)
Net Margin = 4.20% (Net Income TTM 125.6m / Revenue TTM 2.99b)
Gross Margin = 26.92% ((Revenue TTM 2.99b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 28.91% (prev 25.67%)
Tobins Q-Ratio = 0.56 (Enterprise Value 3.56b / Total Assets 6.38b)
Interest Expense / Debt = 4.59% (Interest Expense 110.2m / Debt 2.40b)
Taxrate = 4.85% (6.40m / 132.0m)
NOPAT = 221.0m (EBIT 232.2m * (1 - 4.85%))
Current Ratio = 1.10 (Total Current Assets 1.19b / Total Current Liabilities 1.08b)
Debt / Equity = 0.95 (Debt 2.40b / totalStockholderEquity, last quarter 2.52b)
Debt / EBITDA = 6.21 (Net Debt 2.13b / EBITDA 342.3m)
Debt / FCF = 10.39 (Net Debt 2.13b / FCF TTM 204.8m)
Total Stockholder Equity = 2.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.97% (Net Income 125.6m / Total Assets 6.38b)
RoE = 4.99% (Net Income TTM 125.6m / Total Stockholder Equity 2.52b)
RoCE = 4.93% (EBIT 232.2m / Capital Employed (Equity 2.52b + L.T.Debt 2.20b))
RoIC = 4.27% (NOPAT 221.0m / Invested Capital 5.18b)
WACC = 4.53% (E(1.43b)/V(3.83b) * Re(4.81%) + D(2.40b)/V(3.83b) * Rd(4.59%) * (1-Tc(0.05)))
Discount Rate = 4.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.86 | Cagr: -6.58%
[DCF] Terminal Value 73.10% ; FCFF base≈269.6m ; Y1≈236.4m ; Y5≈191.0m
[DCF] Fair Price = 6.72 (EV 3.07b - Net Debt 2.13b = Equity 938.9m / Shares 139.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 44.50 | EPS CAGR: 2.42% | SUE: 4.0 | # QB: 2
Revenue Correlation: -44.64 | Revenue CAGR: -0.51% | SUE: 0.53 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.45 | Chg30d=-8.45% | Revisions=-50% | Analysts=5
EPS current Year (2026-12-31): EPS=1.43 | Chg30d=-4.47% | Revisions=-17% | GrowthEPS=-14.0% | GrowthRev=-2.9%
EPS next Year (2027-12-31): EPS=1.49 | Chg30d=-8.39% | Revisions=-17% | GrowthEPS=+4.1% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: -42% (up=2, down=7)